If you can't read this email, click here

Quality and dynamism are the two main characteristics of clinical research activity in the Bordeaux region. A few months after its operational launch, ACCELENCE is already supporting over 50 industry-sponsored clinical trials with dedicated medical and paramedical human resources. We are especially pleased to present this first report.

For each edition from now on, the ambition of this Newsletter will be to highlight a specific clinical department, as well as a company involved in biomedical research. In this publication, the accent will be on the pediatrics department at the Pellegrin Children’s Hospital and on the presentation of a talented SME with skills that are unique in France, FLUOFARMA (high-content screening services and technology), a shareholder of the Industrial Research Support Company (SARI), one of ACCELENCE’s founding members.

Set up in 1992, the Bordeaux Children’s Hospital sees 18,000 patients per year, in over 55,000 consultations.

Contributor to over 35 clinical trials, the Bordeaux Pediatric Clinical Investigation Center (CIC), managed by Professor Michaël FAYON, has long demonstrated its commitment to developing research in the Aquitaine region. To date 11 clinical trials are supported within the Pediatric CIC by ACCELENCE teams to the benefit of industrial sponsors such as GILEAD SCIENCES, GLAXO SMITHKLINE, NOVARTIS or PIERRE FABRE, or CROs such as PAREXEL.

Among the numerous pathologies treated in this hospital, three fields are particularly worthy of attention:


One of only 2 French hospitals with a pediatric dermatology department, the Bordeaux Children’s Hospital sees in this department 4,500 patients per year. The environment is favorable, as the Bordeaux University Hospital is one of 3 French centers accredited by Orphanet for the treatment of rare skin diseases (accredited in 2005, renewed in 2011): http://www.orpha.net

Managed by Professor Alain TAÏEB, the Bordeaux University Hospital dermatology department has internationally-recognized expertise for the diagnosis and support of orphan and rare skin diseases, namely genetic diseases, pigmentation diseases (giant nevi, vitiligo, albinism and other hypomelanoses) and photoprotection diseases (xeroderma pigmentosum, trichothiodystrophy, congenital erythropoietic porphyria) as well as angiomas and vascular malformations. Its pediatric dermatology unit, headed by Professor Franck BORALEVI, also supports common diseases, in their difficult and serious forms, in particular atopic dermatitis for which clinical research programs in dermatology and allergy are in progress as well as multidisciplinary consultations (dermatology and allergy); and inflammatory or autoimmune diseases (dermatology & rheumatology consultation for systemic diseases).

  Cystic fibrosis

The Bordeaux Children’s Hospital is one of the French centers specialized in treatment of this disease.

Very much involved in screening for cystic fibrosis in newborns, Bordeaux is also pioneering clinical research: 160 children are regularly monitored, most of which were diagnosed by testing during their 3rd day of life. Managed by Professor Michaël FAYON and Doctor Stéphanie BUI, the Bordeaux University Hospital pediatric center for cystic fibrosis resources and skills (CRCM) is composed of a multidisciplinary care team: pediatricians specialized in pneumology, gastroenterology or genetics; pediatric nurses; physiotherapists; psychologists; dieticians… In addition this pediatric branch of the CIC (INSERM Clinical Investigation Center), along with the adult pneumology CIC and the INSERM units, is one of 15 European reference research centers in this field: http://www.ecfs.eu/ctn/list-ctn-centres

  Neonatology and nutrition

With 5,000 births per year the Bordeaux University Hospital maternity ward is one of the largest in France.

80 % of the newborns are breastfed at birth (70 % is the national average). The maternity ward sees 90 % of premature infants born at less than 32 weeks in the Aquitaine region, or around 500 newborns per year. Under the impulse of Doctor Claude BILLEAUD, the neonatology department is very much involved in clinical research. It is authorized to test all formula milk for premature infants and newborns. The department is namely specialized in lipid determination and lipoperoxidation. In addition it is equipped with a chromatograph to measure volatile aldehydes.
Fluofarma is a leading company in High Content Screening (HCS) providing services to improve the drug discovery potential of its clients.

  Fluofarma know-how

Fluofarma combines unparalleled know-how in cell biology, assay development, cutting-edge High Content Screening technologies and exclusive data mining capabilities to support drug discovery programs.

  Fields of application

Fluofarma has built a deep knowledge in numerous fields such as oncology, neurobiology, drug toxicity, cardiology and cosmetics. However Fluofarma technologies can be applied to all fields of drug discovery.

  Fluofarma's offer

The Fluofarma divisions provide the most complete High Content Screening service offer on the market.


- Development of new cell-based assay
- Customization of cell-based assay
- Miniaturization of cell-based assay
- Mechanism Of Action studies
- Tissue Imaging and Biomarkers


- High content screening operational capacity
- Portfolio of over 600 validated cell-based assays
- 40 different cellular models including cell primary cultures or 3D microtissues


- Custom development of software applications for HCS
- Image and data analysis

Over 70 major pharmaceutical and biotechnology companies worldwide have already used Fluofarma services to evaluate the effects of their compounds.
To date, the ACCELENCE team in investigation centers counts 5 co-investigating physicians (cardiology, dermatology & oncology, oncology, pediatrics), 3 CRA (pediatrics, endocrinology, internal medicine & infectious diseases, neurology), 1 laboratory technician and 1 pediatric nurse. These human resources are deployed over 52 clinical trials, aiming for a potential 300 patients.

Tel : +33 (0)5 56 48 95 10 - Email : contact@accelence.org